Macular edema

Macular edema is not a molecular target or receptor, but rather a clinical condition characterized by the swelling or thickening of the macula—the central part of the retina responsible for detailed vision. This swelling results from fluid accumulation due to leakage from damaged or abnormally permeable retinal blood vessels. The underlying cause is often a breakdown in the blood-retinal barrier, leading to increased vascular permeability and subsequent fluid retention within retinal layers. Macular edema can arise as a complication of various diseases such as diabetic retinopathy, retinal vein occlusion, uveitis, age-related macular degeneration, post-surgical inflammation (notably after cataract surgery), trauma, and certain medications. It presents clinically with symptoms like blurred central vision and distortion but may be asymptomatic in early stages. Diagnosis relies on clinical examination and imaging modalities such as OCT that reveal thickening or cystic changes in the macula. Treatment targets underlying causes—most commonly using anti–VEGF agents or corticosteroids delivered via intravitreal injection—to reduce vascular leakage and control inflammation[1][2][3][4][5][6][7][8][9]. Note: "Macular edema" is not itself a protein/receptor/enzyme/therapeutic target; it is a pathological state resulting from multiple upstream molecular mechanisms involving inflammatory mediators like VEGF and cytokines. Thus it should not be classified as a canonical drug target; instead therapies are directed at molecules involved in its pathogenesis such as VEGF.

Other names

Macular oedemaCystoid macular edema (CME)Diabetic macular edema (DME)

Inhibition of vascular endothelial growth factor to reduce vascular permeability and leakage; Suppression of inflammation to decrease fluid accumulation in the retina[9]